Physician profile
Mary E Daly
NPI 1679668313
$1,551.75
in general payments reported to CMS, 2019-2025
8 companies · $40.60 in 2025
The $40.60 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.54 · 2022: $233 · 2023: $411 · 2024: $805 · 2025: $40.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Education: $8.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.79 |
| Education | $8.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $682.52 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $410.06 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $118.47 | 2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $105.63 | 2024 | Rexulti |
| Atricure, INC. | $85.92 | 2024 | |
| Alkermes, INC. | $76.16 | 2024 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $51.12 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $21.87 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.